Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Exanthema 2Pneumonia, Pneumocystis 1Leukoplakia, Oral 1HIV Infections 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Candidiasis, Oral 1AIDS-Related Opportunistic Infections 1AIDS-Related Complex 1

Interventions

Gels 2Fulvestrant 2Doxycycline 2Dapsone 2ruxolitinib 1dexpanthenol 1ceterizine hydrochloride 1capivasertib 1benralizumab 1Triamcinolone Acetonide 1Tetracycline 1Sirolimus 1Provitamins 1Prednisone 1Panitumumab 1Minocycline 1Loperamide 1Irinotecan 1IFL protocol 1Hydrocortisone 1Erlotinib Hydrochloride 1Clindamycin 1Cetuximab 1Anti-Bacterial Agents 1Alpelisib 1Acitretin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Exanthema × Dapsone × Clear all
NCT01931150 2017-01-13

Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT

Memorial Sloan Kettering Cancer Center

Phase 3 Completed
11 enrolled 7 charts
Gastrointestinal

Exanthema, Colorectal Neoplasms

NCT00343187 2011-05-30

A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash

Allergan

Phase 2 Terminated
2 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Exanthema

Data powered by HemOnc (CC BY 4.0) Colophon âš¡